Bristol-Myers Squibb in integrity agreement as part of settlement

Share this article:

Bristol-Myers Squibb (BMS) has entered into a corporate integrity agreement (CIA) with the Office of Inspector General of the Department of Health and Human Services as part of a civil settlement to resolve allegations that the company inflated its drug prices and was involved in kickbacks to doctors.

Under the terms of the CIA, the drugmaker will be required to report its average sales prices and average manufacturer prices for drugs covered by Medicare and other federal health care programs for a five-year term.

Among the other obligations contained in the 80-page CIA are the continued development and maintenance of the company's compliance programs related to its US pharmaceuticals business.

The terms of the integrity agreement will not affect BMS' ongoing business with customers or the government, the drugmaker said in a statement.

Additional terms of the civil settlement require BMS to pay $515 million in penalties.

There were no criminal charges filed against the company.

 

Share this article:
close

Next Article in News

Email Newsletters

More in News

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

Executives urge analysts to focus on the company's long-term potential.

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union